The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold its 20th Annual International Meeting, May 16-20, 2015 in Philadelphia, PA, USA.
Speakers at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), held May 18th to 20th in Philadelphia, discussed the status of the Learning Health Care System in their first plenary session, entitled “Taking Stock of the Learning Health Care System: What Have We Achieved and Why Does it Matter?”
Issues surrounding cost effectiveness and related clinical questions were taken up in the Second Plenary Session at the ISPOR 20th Annual International Meeting, entitled, “Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?”
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its 20th Annual International Meeting May 16-20, 2015 in Philadelphia. The Meeting marked ISPOR’s 20th anniversary and focused on the theme of Integrating Big Data, Patient Data, and Cost-Effectiveness into Clinical Practice: Promise and Prospects.
The ISPOR 2015 “Scientific Achievement Awards” were announced on the second day of the meeting on Tuesday, May 19, 2015. The ISPOR Awards Program is designed to foster and recognize excellence and outstanding technical achievement in pharmacoeconomics / health economics and outcomes research. In addition to scientific achievement, ISPOR also awards lifetime achievement and leadership awards to those who advance these disciplines in the field and by service to the Society.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced the Society’s 2015-2016 Board of Directors. The new officers and directors assume office on July 1, 2015.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced an agreement with CAC (the High Cost Disease Fund of Colombia), an organization within the Colombia Ministry of Health, dedicated to addressing issues surrounding the significant budget impact of high cost diseases in the country.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that its 18th Annual European Congress has registered a record number of delegates for this annual meeting. The Congress will be held 7-11 November 2015 in Milan, Italy.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published results of an expansive global review answering a basic scientific question, “How do you describe a ‘rare disease?’” in “Rare Disease Terminology and Definitions.”
The International SISPOR) announced that Betsy Lane has been appointed director and chief marketing and communications officer for the organization.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced confirmation of key scientific sessions for its 18th Annual European Congress starting next week, 7-11 November 2015, in Milan, Italy.
ISPOR published a new Task Force Report, “Clinical Outcome Assessments (COAs): A Conceptual Foundation – Report of the ISPOR Clinical Outcomes Assessment Emerging Good Practices Task Force,” in Value in Health.
ISPOR's 18th Annual European Congress first plenary session — Strategy in Motion: The Current and Future Lifecycle Approach to Decision Making on Health Technologies — was held this morning at the MiCo – Milano Congressi in Milan, Italy.
ISPOR 18th Annual European Congress Issue Panel 1 explored, “What Is the Role of Economic Evaluation in Pricing and Reimbursement of Medicines: A Comparison Between England, Germany, and France.”
ISPOR 18th Annual European Congress Issue Panel 2 explored the issue of, “Possible Increased Synergy Between Health Technology Assessment (HTA) and Regulatory Agencies: Opportunity or Challenge for Medical Devices?.”
ISPOR outlined the organization’s updated strategic vision this morning during its member meeting at the 18th Annual European Congress in Milan, Italy.
ISPOR 18th Annual European Congress second plenary session — Outcomes Research: Are We Ready to Put Theory into Practice? — was held this morning at the MiCo – Milano Congressi in Milan, Italy.
ISPOR 18th Annual European Congress Workshop 12 focused on the issue of, “Optimizing Patient Involvement in Payer Health Care Decisions to Access New Therapies.”
ISPOR's 18th Annual European Congress third plenary session — Recommendations from the ISPOR Multi-Criteria Decision Analysis Emerging Good Practice Task Force and Remaining Controversies — was held this morning at the MiCo – Milano Congressi in Milan, Italy.
ISPOR recognized its 2015 ISPOR Award recipients at the 18th Annual European Congress in Milan, Italy.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress recently concluded in Milan, Italy. Health ministries and government officials from more than 40 countries convened in Milan on 7-11 November, 2015 with over 5,000 ISPOR delegates.
ISPOR announced today a new Student Network benefit that now provides ISPOR student members with complimentary access to FormularyDecisions.com®.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Denmark Pharmaceuticals. ISPOR Global Health Care Systems Road Maps provide an overview of country-specific, health care delivery systems.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that its Latin America Consortium Publications Committee has published its first Science Policy Brief—Budget Impact Analysis: New Norms (El Análisis del Impacto Presupuestario: Nuevas Normas).
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published a new Task Force Report, “Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force,” in the January/February 2016 issue of Value in Health (Volume 19, Issue 1).
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced its three plenary sessions and speakers for the 21st Annual International Meeting that will be held May 21–25, 2016 in Washington, DC, USA. Each of the three plenary sessions will explore the concepts of the conference theme—Value, Affordability, and Patient Centeredness: Can We Have It All?.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced its candidates today for open positions on the 2016–2017 Board of Director.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today the recipients of its 2016 Scientific Achievement Awards. The ISPOR Awards Program is designed to foster and recognize excellence and outstanding technical achievement in HEOR.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced its next Health Technology Assessment (HTA) Training Program will be held in Lisbon, Portugal from 26-29 June 2016.
ISPOR published a new Task Force Report, “Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force, ” in the March/April 2016 issue of Value in Health.
ISPOR announced today the launch of its new interactive job board, the ISPOR Career Center. With its global focus on health economics and outcomes research (HEOR), the ISPOR Career Center offers job seekers and organizations seeking candidates with HEOR expertise an easy-to-use and highly targeted resource for online employment connections.
ISPOR announced today that it is expanding its leadership team with the appointment of Richard J. Willke, PhD as Chief Science Officer for the organization.
ISPOR announced today that it has published a new Global Health Care Systems Road Map—Australia Medical Devices.
ISPOR announced confirmation of key scientific sessions for its 21st Annual International Meeting starting next week, May 21-25, 2016 in Washington, DC, USA. The meeting will feature three, timely Plenary Sessions centered on the theme, “Value, Affordability, and Patient Centeredness: Can We Have It All?”.
ISPOR opened its 21st Annual International Meeting this morning with the first plenary session, Accelerating Cures: Addressing Unmet Patient Need or Putting Patients at Risk?, in Washington, DC, USA.
ISPOR 21st Annual International Meeting Issue Panel 5—Use of Real-Word Evidence in Payer Decision Making: Fact or Fiction?—was held this morning in Washington, DC, USA.
ISPOR 21st Annual International Meeting Workshop 2—Risk-Sharing Agreements for Manufacturers and Commercial Payers in the United States: How Can Theory Help Practice? Design and Aligning Incentives Are Key—was held this afternoon in Washington, DC, USA.
ISPOR recognized its 2016 Awards Program recipients at the 21st Annual International Meeting in Washington, DC, USA. The ISPOR Awards Program is designed to foster and recognize excellence and outstanding technical achievement in health economics and outcomes research (HEOR).
The second ISPOR plenary session on Making Medical Decisions in an Irrational World was held this morning at the Society’s 21st Annual International Meeting in Washington, DC, USA.
ISPOR's 21st Annual International Meeting Issue Panel 12—Multi-Criteria Decision Analysis: A New Paradigm in Health Care Decision Making? What Are the Current Status, Challenges, and Opportunities?—was held this afternoon in Washington, DC, USA.
The ISPOR 21st Annual International Meeting Workshop 13—Patients as Partners in Research—Making It a Reality—was held this afternoon in Washington, DC, USA.
The ISPOR 21st Annual International Meeting Issue Panel 18—Precision Medicine: The End of Outcomes Research?—was held this morning in Washington, DC, USA.
The ISPOR 21st Annual International Meeting Issue Panel 20—What Is the Value of Frameworks to Patients? The Case in Oncology—was held this morning in Washington, DC, USA.
The ISPOR 21st Annual International Meeting Workshop 23—Methodologies for Evaluating Geospatial Access in Medication Use Studies—was held this afternoon in Washington, DC, USA.
The third plenary session for ISPOR's 21st Annual International Meeting—Contemporary Regulatory and Legislative Issues in Health Outcomes Research—was held this morning in Washington, DC, USA.
ISPOR announced today that CEO and Executive Director Nancy Berg has been recognized as a transformational leader by PM360’s annual ELITE award program.
ISPOR's 21st Annual International Meeting recently concluded in Washington, DC, USA. Government officials, health ministries, and global thought leaders in health economics and outcomes research (HEOR) from more than 80 countries convened in the US capital during an election year on May 21–25, 2016.
ISPOR announced its plenary sessions and speakers for its 7th Asia-Pacific Conference that will be held 3-6 September 2016 in Singapore. The plenary sessions will explore concepts related to the conference theme—Pharmacoeconomics and Outcomes Research in Asia-Pacific: Challenges, Opportunities, and Future Direction.
New data released by Thomson Reuters' Journal Citation Reports show that Value in Health is ranked as one of the top journals in the health policy and sciences category, ranking 3rd among 74 journals in the field. . This year's data show that Value in Health's impact factor score has increased by 16.6% to 3.824. This is the third year in a row that the journal has shown double-digit growth in the percentage of improvement in its impact factor score.
ISPOR has published its third Good Research Practices Task Force Report on preference-based methods that measure patient and other stakeholder preferences. The report appears in the June 2016 issue (Volume 19, Issue 4) of Value in Health.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right